Tachykinin receptor antagonists in clinical trials (Q37638682)

21 August 2017

1 reference

title

Tachykinin receptor antagonists in clinical trials (English)

1 reference

21 August 2017

0 references

Laura Quartara

1 reference

21 August 2017

Maria Altamura

series ordinal

1 reference

21 August 2017

Stefano Evangelista

series ordinal

1 reference

21 August 2017

Carlo A Maggi

series ordinal

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

published in

1 reference

21 August 2017

1 reference

21 August 2017

1 reference

21 August 2017

page(s)

1843-1864

1 reference

Potential therapeutic targets for neurokinin-1 receptor antagonists

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Neuroactive substances in the dorsal vagal complex of the medulla oblongata: nucleus of the tractus solitarius, area postrema, and dorsal motor nucleus of the vagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

NK1 (substance P) receptor antagonists--why are they not analgesic in humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Multicomponent therapeutics for networked systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

The effect of CP-99994 on the responses to provocative motion in the cat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III ran

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Prevention of postoperative nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Lack of self-administration and behavioural sensitisation to morphine, but not cocaine, in mice lacking NK1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Neurokinin-1 receptor antagonist (aprepitant) suppresses HIV-1 infection of microglia/macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Peripheral tachykinin receptors as targets for new drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Pilot evaluation of aprepitant for the treatment of hot flashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Tachykinins and their functions in the gastrointestinal tract.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Expression of tachykinin NK2 receptor mRNA in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Expression of the neurokinin type 1 receptor in the human colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Tachykinins and tachykinin receptors in the gut, with special reference to NK2 receptors in human

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Role of tachykinin NK2 receptors in normal and altered rectal sensitivity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Responses of rat spinal neurons to distension of inflamed colon: role of tachykinin NK2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Role of NK2 receptors in gastric barosensitivity and in experimental ileus in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

The triple neurokinin-receptor antagonist CS-003 inhibits neurokinin A-induced bronchoconstriction in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

The NK-2 receptor antagonist SR 48968C does not improve adenosine hyperresponsiveness and airway obstruction in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Tachykinins and tachykinin receptors: structure and activity relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Detailed distribution of Neurokinin 3 receptors in the rat, guinea pig and gerbil brain: a comparative autoradiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Tachykinin receptors and tachykinin receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Behavioural effects of selective tachykinin agonists in midbrain dopamine regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Neurokinin-3 receptor-specific antagonists talnetant and osanetant show distinct mode of action in cellular Ca2+ mobilization but display similar binding kinetics and identical mechanism of binding in ligand cross-competition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Defensive and pathological functions of the gastrointestinal NK3 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903379530

10.1517/13543780903379530

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference